DelveInsight’s “Generalized Myasthenia Gravis (gMG) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Generalized Myasthenia Gravis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Generalized Myasthenia Gravis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Generalized Myasthenia Gravis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Generalized Myasthenia Gravis (gMG): An Overview
Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body’s own tissues. In MG, that attack interrupts the connection between nerve and muscle—the neuromuscular junction. MG is characterized mostly by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab).
The diagnosis of MG is mostly clinical, and laboratory investigations and procedures usually aid the clinician in confirming the clinical findings. The diagnosis of MG is done through various tests such as serological tests, endrophonium tests, ice-pack tests, imaging, and other laboratory tests. MG remains one of the most challenging medical diagnoses due to its fluctuating character and the similarity of its symptoms to those of other disorders, as there are no international consensus guidelines.
Generalized Myasthenia Gravis (gMG) Market Key Facts
The total number of diagnosed prevalent cases of Generalized Myasthenia Gravis associated in the 7MM countries was approximately 116,100 in 2021.
In 2021, the total prevalent cases of gMG were the highest in the US, with approximately 40,000 cases, and lowest in Italy with approximately 8,800 cases.
There were approximately 13,500 males and 26,500 females affected by gMG in the United States in 2021 and it is estimated that the prevalence will increase and reach up to 15,500 and 30,300 in males and females by 2032.
Among EU5 countries, Germany had the highest number of prevalent cases of Generalized Myasthenia Gravis (gMG) (~14,700 cases) in 2021.
Italy had the lowest prevalent population of Generalized Myasthenia Gravis (gMG) (8,800 cases) in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Generalized Myasthenia Gravis therapies in the market. It also provides a detailed assessment of the Generalized Myasthenia Gravis market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the market trend for each marketed Generalized Myasthenia Gravis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Generalized Myasthenia Gravis (gMG) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Generalized Myasthenia Gravis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Generalized Myasthenia Gravis Epidemiology Segmented as –
Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) [2019–2032]
Gender-Specific Cases of Generalized Myasthenia Gravis (gMG) [2019–2032]
Autoantibodies-Specific Cases of Generalized Myasthenia Gravis (gMG) [2019–2032]
Generalized Myasthenia Gravis Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Myasthenia Gravis market or expected to be launched during the study period. The analysis covers the market share by Generalized Myasthenia Gravis drugs, patient uptake by therapies, and sales of each drug.
The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Generalized Myasthenia Gravis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover How the Generalized Myasthenia Gravis Market will Grow by 2032 @
Generalized Myasthenia Gravis (gMG) Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Generalized Myasthenia Gravis (gMG). Currently, Roche is leading the therapeutics market with its Generalized Myasthenia Gravis (gMG) drug candidates in the most advanced stage of clinical development.
Generalized Myasthenia Gravis (gMG) Companies in the Therapeutics Market Include:
AbbVie Inc., Alexion Pharmaceuticals, Amgen Inc., Argenx, Argenx-Halozyme Therapeutics, AstraZeneca plc, Biocon, Biogen, BioMarin, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cartesian Therapeutics, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, HanAll Biopharma, Hoffmann-La Roche, Horizon Therapeutics, Immunovant Sciences GmbH, Janssen Research & Development, LLC, Johnson & Johnson, Merck & Co., Inc., Momenta Pharmaceuticals, Novartis AG, Pfizer Inc., Roche, Takeda Pharmaceutical Company Limited, UCB Biopharma, Vertex Pharmaceuticals Incorporated, and others.
Generalized Myasthenia Gravis (gMG) Therapies Covered in the Report Include
Nipocalimab: Prevention Bio
Rozanolixizumab: UCB Biopharma
Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics
Zilucoplan: UCB Biopharma
Uplizna (Inebilizumab): Horizon Therapeutics
Enspryng (Satralizumab): Hoffmann-La Roche
Nipocalimab: Janssen Research & Development, LLC
Batoclimab: Immunovant Sciences GmbH
Descartes-08: Cartesian Therapeutics
Mezagitamab (TAK-079): Takeda
DAS-001: DAS Therepeutics, Inc.
And Many Others
Learn More About the Emerging Therapies & Key Companies in the Generalized Myasthenia Gravis Therapeutics Market @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Generalized Myasthenia Gravis Competitive Intelligence Analysis
4. Generalized Myasthenia Gravis Market Overview at a Glance
5. Generalized Myasthenia Gravis Background and Overview
6. Generalized Myasthenia Gravis Patient Journey
7. Generalized Myasthenia Gravis Epidemiology and Patient Population
8. Generalized Myasthenia Gravis Treatment Algorithm, Current Treatment, and Medical Practices
9. Generalized Myasthenia Gravis Unmet Needs
10. Key Endpoints of Generalized Myasthenia Gravis Treatment
11. Generalized Myasthenia Gravis Marketed Products
12. Generalized Myasthenia Gravis Emerging Therapies
13. Generalized Myasthenia Gravis Seven Major Market Analysis
14. Attribute Analysis
15. Generalized Myasthenia Gravis Market Outlook (7 major markets)
16. Generalized Myasthenia Gravis Access and Reimbursement Overview
17. KOL Views on the Generalized Myasthenia Gravis Market.
18. Generalized Myasthenia Gravis Market Drivers
19. Generalized Myasthenia Gravis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Global Stereotactic Surgery Devices Market is projected to grow at a 5.37% CAGR during the forecast period from 2023 to 2028. The demand for stereotactic surgery devices is primarily witnessing an increase due to the rising incidence of various cancers such as brain cancers, increasing prevalence of movement disorders such as Parkinson’s disease, the growing popularity of minimally invasive stereotactic radiosurgery and radiotherapy, and innovation in product development, among others.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States